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KAJIAN ANTI-KANSER GARCINIA MANGOSTANA L. DAN SYZYGIUM 
CAMPANULATUM KORTH TERHADAP KANSER USUS 
 
ABSTRAK 
Kajian ini bertujuan untuk menyiasat aktiviti antiangiogenik dan antikanser kolon 
ekstrak dan isolat-isolat Syzygium campanulatum dan Garcinia mangostana. Kajian ini 
juga bertujuan untuk menyediakan ekstrak toluene G. mangostana. dalam bentuk 
nanopartikel dan α-mangostin dalam serakan pepejal untuk meningkatkan kelarutannya 
dalam akueus. Analisis fitokimia ekstrak S. campanulatum secara relatifnya 
menunjukkan kehadiran asid betulinic dan kandungan polifenol dengan kepekatan yang 
agak tinggi. Asid betulinik  daripada ekstrak S. campanulatum tersebut menunjukkan  
sitotoksik yang poten ke atas sel-sel kanser kolon dengan melalui induksi laluan 
apoptosis mitokondria. Ekstrak-esktrak S. campanulatum tersebut menunjukkan kesan 
perencatan poten angiogenesis dalam beberapa model in vitro dan in vivo dengan 
menghalang ungkapan faktor pertumbuhan endotelial vaskular dan menghalang 
penghijrahan sel-sel endotelial manusia. Ekstrak metanol menghalang pertumbuhan 
tumor dalam model xenograft tumor dengan perencatan ketara saluran darah intratumor. 
α- dan γ-mangostin telah diasingkan daripada kulit buah G. mangostana, dan telah 
dibangunkan untuk menyeragamkan ekstrak-ekstrak G. mangostana oleh UV 
spektrofotometri dan kaedah HPLC.  Mangostins terpencil dan ekstrak-ekstrak xanton 
menunjukkan sitotoksiti poten ke atas sel-sel kanser kolon dengan melalui induksi 
laluan apoptosis mitokondria, dan juga menunjukkan kesan in vitro anti-tumorigenisiti. 
Sebatian-sebatian itu mendorong aktiviti faktor transkripsi isyarat laluan p53, Myc/Max 
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dan MAPK/ERK dan menghalang laluan NF-KB. Ekstrak toluena G. mangostana 
menunjukkan perencatan pertumbuhan tumor in vivo yang ketara dengan permulaan 
yang lambat. Ekstrak-ekstrak G. mangostana dan S.C. tidak menunjukkan kesan toksik 
dan nilai LD50 dalam tikus Sprague Dawley didapati lebih daripada 2000 mg/kg berat 
badan. 
Nanopartikel kationik toluena ekstrak G. mangostana telah disediakan melalui kaedah 
nanopresipitasi dalam polimer Eudragit RL100 dan RS100. Saiz zarah berada di bawah 
70 nm dengan kecekapan perangkap tinggi (> 90%). Nanopartikel dikumpulkan dengan 
kadar hasil >90% oleh pengeringan sejuk beku larutan nanopartikel pukal. 
Kebolehlarutan ekstrak meningkat secara drastik, dan penghantaran intraselular 
nanopartikel menyebabkan sitotoksisiti poten kepada sel-sel kanser kolon. Perencatan 
pertumbuhan tumor in vivo telah dicapai pada permulaan awal dalam rawatan 
nanopartikel berbanding kepada ekstrak yang bukan formulasi. Kepekatan α-mangostin 
dalam dinding saluran gastrousus haiwan yang dirawat dengan nanopartikel adalah 
lebih tinggi berbanding dengan yang dirawat dengan ekstrak bukan formulasi. Serakan 
pepejal α-mangostin dalam polyvinylpyrrolidone menghasilkan kebolehlarutan 
kompaun dengan menggalakkan pemasangan sendiri nanomiseles, pengurangan saiz 
zarah, dan pembentukan mendakan yang amorfus dan sangat telap. Penghantaran 
intraselular α-mangostin menyebabkan sitotoksisiti penting kepada sel-sel kanser kolon 
in vitro.  
S. campanulatum boleh menyediakan sumber baru asid betulinik dan ekstrak tersebut 
mungkin mempunyai aplikasi terapeutik untuk pencegahan kemo dan rawatan kanser 
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kolon. Sistem penyampaian ubat mangostins boleh menjadi aplikasi menarik untuk 
rawatan kanser kolon. 
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ANTI-CANCER STUDIES OF GARCINIA MANGOSTANA L. AND SYZYGIUM 
CAMPANULATUM KORTH TOWARDS COLORECTAL CARCINOMA 
 
ABSTRACT 
This study aims to investigate the anti-angiogenic and anti-colon cancer activity of the 
extracts and isolates of Syzygium campanulatum and Garcinia mangostana. And to 
prepare G. mangostana toluene extract in nanoparticles and α-mangostin in solid 
dispersions in order to improve their aqueous solubility. Phytochemical analysis of S. 
campanulatum extracts reveals relatively high concentration of betulinic acid (BA) and 
polyphenols. BA fraction from S. campanulatum showed potent cytotoxicity on colon 
cancer cells by inducting the mitochondrial pathway of apoptosis. Extracts also showed 
potent inhibition of angiogenesis in several in vitro and in vivo models, by inhibiting the 
expression of vascular endothelial growth factor and inhibiting migration of human 
endothelial cells. The methanolic extract also inhibits tumor growth in xenograft tumor 
model with inhibition of intratumor blood vessels.  
α- and γ-mangostin were isolated from G. mangostana fruit rinds, and were used to 
standardize the G. mangostana extracts by UV spectrophotometric and HPLC methods. 
The isolates and the xanthone extracts demonstrated potent cytotoxicity on colon cancer 
cells by inducing the mitochondrial apoptosis pathway, and also showed effective in 
vitro anti tumorigenicity. The compounds induced the transcription factor activity of 
p53, Myc/Max and MAPK/ERK signaling pathways and inhibit the NF-KB pathway. 
The toluene extract of G. mangostana showed significant delayed onset inhibition of 
tumor growth in vivo. S. campanulatum and G. mangostana extracts did not show 
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severe toxic effects and the LD50 in Sprague Dawley rats was more than 2000 mg/kg 
body weight. Cationic nanoparticles of G. mangostana toluene extract were prepared by 
the nanoprecipitation method in Eudragit polymers RL100 and RS100. Particle size was 
below 70 nm with high entrapment efficiency (>90%). Nanoparticles were collected at 
>90% yield by freeze drying of the bulk nanoparticle solutions. Solubility of extract 
improved drastically, and the intracellular delivery of nanoparticles caused potent 
cytotoxicity towards colon cancer cells. Inhibition of tumor growth in vivo was 
achieved at earlier onset in the nanoparticles treatment compared to non-formulated 
extract. Concentration of α-mangostin in gastrointestinal tract wall was higher in 
nanoparticles treated animals than in those treated with non-formulated extract. Solid 
dispersions of α-mangostin in polyvinylpyrrolidone resulted in improved compound’s 
solubility by inducing self assembly of nanomicelles, particle size reduction, and 
formation of amorphous and highly porous co-precipitates. And intracellular delivery of 
α-mangostin caused significant cytotoxicity towards colon cancer cells in vitro.  
S. campanulatum may provide a new source of BA and its extracts may have 
therapeutic application in colon cancer chemoprevention and treatment. The drug 
delivery systems of mangostins may find interesting applications in colon cancer 
treatment.  
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1.1 Angiogenesis: 
1.1.1 Definition and Role in Physiology and Disease:  
Angiogenesis is the formation of new blood vessels from pre-existing vessels. It is a 
biological process that plays fundamental roles in embryonic development. It also has a 
critical role in normal physiological situations such as in the female reproductive tract, 
in the placenta during pregnancy and during wound healing (Auerbach et al., 2003; 
Folkman, 1995; Vailhe et al., 2001). Angiogenesis is a regulated process while 
pathological angiogenesis is a deregulated and believed to play a key role in several 
pathological conditions including proliferative retinopathies, atherosclerosis, 
rheumatoid arthritis, psoriasis, tumor growth and metastasis (Creamer et al., 2002; 
Folkman, 1995). Since tumor angiogenesis is essential for growth and metastasis of 
most solid malignancies, it has became one of the  main targets of new cancer therapies 
(Eatock et al., 2000; Hurwitz et al., 2004; Pfeffer et al., 2003; Scappaticci, 2003). 
Besides the inhibition of angiogenesis, enhancement of the angiogenesis cascade to 
stimulate the formation of new microvessels in the myocardium is considered as a target 
for treatment of ischemic heart diseases (Tabibiazar and Rockson, 2001). Therefore, 
compounds with either anti-angiogenic or proangiogenic effects could be good 
therapeutic candidates for the treatment of life threatening diseases such as cancer and 
ischemic heart diseases.  
1.1.2 Angiogenesis - Cascade of Events: 
To develop effective angiogenesis modulators, it is crucial to understand the 
mechanisms underlying the process. Several but tightly regulated steps are involved in 
the formation of new blood vessels including disintegration of the extracellular matrix 
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underlying the endothelium, migration, adhesion, and proliferation of endothelial cells, 
assembly into three-dimensional tubular structure and finally maturation into functional 
microvessels that support blood flow (Tabibiazar and Rockson, 2001; Papetti and 
Herman, 2002). Each step can be modulated by several factors and may give the ability 
to control the process, and hence can be a target for treatment of angiogenesis related 
diseases.  
1.1.3 Regulation of Angiogenesis:  
As a tightly regulated process, regulation of angiogenesis depends on the balance 
between the proangiogenic (stimulators) and the anti-angiogenic (inhibitors) 
modulators. In their review article, Liekens and his co-workers divided the regulation of 
angiogenesis into 3 levels; the first is the degradation of the extracellular matrix (ECM), 
the second is the regulation of angiogenic modulators including the growth factors and 
the cytokines and enzymes, and the third level is the cell-cell and the cell-matrix 
interactions (Liekens et al., 2001). The first step in the formation of new vessels is the 
proteolytic breakdown of the basement membrane underlying endothelial cells in order 
for them to migrate and invade the stroma of surrounding tissues. This process requires 
the activity of the plasminogen activators (PAs) and the matrix metalloproteinases 
MMPs (Mignatti and Rifkin, 1996). The activity of both PAs and MMPs is controlled at 
their expression level, at the activation level by the proteolytic enzymes, or at the level 
of their inhibitors such as the tissue inhibitor of metalloproteinase and the inhibitors of 
plasminogen activators (Liekens et al., 2001).  
Subsequent to proteolytic degradation of the ECM and under the influence of a 
variety of growth factors, the frontline endothelial cells start to migrate through the 
 4 
degraded matrix and followed by proliferation of their counterparts. Several modulators 
of angiogenesis including inducers and inhibitors have been described so far including 
the vascular endothelial growth factor (VEGF), fibroblast growth factor-2 (FGF-2), the 
angiopoietins 1 and 2 (Ang-1 and 2), angiostatin, endostatin, interferons α and γ (IFN-α 
and γ) and several other growth factors (Liekens et al., 2001). The regulation of 
angiogenesis depends on the balance between the stimulators and inhibitors of the 
process; when the proangiogenic growth factors predominate, then proliferation and 
migration of endothelial cells is increased and consequently lead to formation of new 
blood vessels and vice versa.  
The cell adhesion molecules, besides the angiogenic enzymes and growth 
factors, play a critical role in regulation of the angiogenesis cascade of events. Cell 
adhesion molecules are classified into 4 families including selectins, the 
immunoglobulin supergene family, cadherins, and the integrins. The integrins for 
example mediate the interaction of endothelial cells with the ECM during invasion and 
migration. Also, the cell adhesion molecules are required for cell–cell and cell–ECM 
interactions which are required for lumen formation and construction of functional 
capillary loops (Bischoff, 1997).  
1.1.4 Tumor Angiogenesis: 
Accumulation of somatic mutations causes transformation of normal cells into 
cancerous cells characterized by uncontrolled proliferation. Consequently, these cells 
begin to divide rapidly resulting in a microscopically small and localized tumor called 
in situ carcinoma (Folkman, 1995). As the tumor grows, the cells in the tumor center are 
getting further and further from the main capillary blood supply and thus they suffer the 
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lack of oxygen and nutrients which can interfere with cell growth leading to cell death. 
Accordingly, the number of proliferating cells counterbalances the number of dying 
cells and hence the tumor stops growing and reaches a steady state (Carmeliet et al., 
1998). These avascular tumors may remain dormant and undetected for many years 
with very rare metastasis (Folkman, 1995). After a period of dormancy and as a result 
of imbalance between the proangiogenic and anti-angiogenic modulators (Giordano and 
Johnson, 2001; Udagawa et al., 2002), the tumor shifts to the angiogenic phenotype 
associated with the formation of intratumor capillaries. As a consequence, the tumor 
grows rapidly and disseminates tumor cells into the blood circulation through the newly 
formed blood vessels which causes secondary tumor growth in distant locations, i.e. 
metastasis (Figure 1.1).     
 
Figure 1.1 Tumor angiogenesis. The figure displays the role of tumor angiogenesis in 
the growth and metastasis of the primary tumor. Adapted from (Ferrara, 2004). 
 
The angiogenesis phenotype can be triggered by the overproduction of positive 
regulators of angiogenesis such as VEGF and FGF-2, down regulation of the negative 
regulators such as the thrombospondin-1 (TSP-1) or by combination of both (Liekens et 
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al., 2001). Several lines of evidence suggest the central role of hypoxia inducible factors 
(HIFs) in tumor angiogenesis, metabolism, proliferation, differentiation and metastasis 
(Rankin and Giaccia, 2008). HIF can directly activate the expression of number of pro-
angiogenic factors such as VEGF, VEGF receptors, plasminogen activator inhibitor-1, 
Ang 1 and 2, platelet-derived growth factor B and MMP-2 and -9 (Hirota and Semenza, 
2006). Of those, VEGF-A is particularly the most important due to its potent angiogenic 
properties, and because it is overexpressed in a large number of human tumors (Dvorak, 
2002). 
The factors causing upregulation of HIFs were reviewed by Hirota and Semenza 
(Hirota and Semenza, 2006); of the included factors are hypoxia, and loss of function 
mutations of succinate dehydrogenases (SDH-B, C and D), mutations in p53 tumor 
suppressor gene and mutations in the phosphatidylinositol-3-kinase/protein kinase 
B/mammalian target of rapamycin pathway (PI3K/AKT/mTOR). For example, under 
hypoxic or even normoxic conditions cancer cells usually obtain their energy from 
glycolysis rather than oxidative phosphorylation which causes accumulation of lactate 
and pyruvate. Recent research shows that pyruvate activates endothelial cells and 
induces angiogenesis by stabilizing HIF-1α (Jung, 2011). The role of the tumor 
suppressor gene p53 was also addressed which enhances the degradation of HIF-1α and 
hence the accumulation of somatic mutations in this gene is associated with increased 
level of HIF-1α and induced tumor angiogenesis (Ravi et al., 2000).  
1.1.5 Impact of Tumor Angiogenesis on Tumor Microenvironment: 
Newly formed tumor blood vessels often have abnormal structure with markedly 
increased diameter, convoluted and disorganized architecture. Their walls may have 
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pores, and are discontinuous or may even lack basement membranes or diminished 
pericyte coverage making the vessels leaky and often filled with interstitial fluid. And 
since tumor tissues have abnormal lymph drainage, the interstitial fluid accumulates 
progressively and consequently the interstitial pressure is increased. As a result, 
resistance to blood flow is increased that impairs blood supply to the tumor and 
consequently lead to decreased delivery of nutrients and oxygen and reduced removal of 
the waste products (Fukumura and Jain, 2007). The lack of oxygen creates hypoxic 
conditions which in combination with the high rate of anaerobic glycolysis lead to 
accumulation of acidic byproducts such as lactic acid and increases the acidity of tumor 
microenvironment (Trédan et al., 2007; Fukumura and Jain, 2007). The reduced 
intratumor blood flow, reduced supply of nutrients, hypoxia and acidosis are believed to 
play a critical role in the success or failure of cancer chemotherapy. The reduced 
intratumor blood blow and the acidic pH hinder the delivery of chemotherapeutics. In 
addition it causes starvation and diminished oxygen supply that result in reduced 
proliferation of tumor cells which become quiescent and less responsive to 
chemotherapy than the rapidly proliferating cells (Trédan et al., 2007). Moreover, the 
persistent hypoxic conditions creates genomic instability that may cause the selection of 
more adaptive tumor cells with more aggressive and resistant phenotypes such as those 
with overexpression of the HIFs, the efflux P-glycoprotein and other survival proteins 
(Trédan et al., 2007). The acidic environment, besides reducing the delivery of 
chemotherapies to the growing tumors, inhibits the cellular uptake and hence reduces 
efficacy of the more alkaline chemotherapeutic drugs such as doxorubicin (Gerweck et 
al., 2006). 
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1.1.6 Mechanisms of Anti-angiogenesis Therapy:  
Mechanistically, anti-angiogenic agents work by interfering with the key steps of 
angiogenesis. Regardless of their target molecules, anti-angiogenic therapy such as anti-
VEGF may cause vasoconstriction, decreased permeability, and decreased perfusion 
resulting in decreased delivery of oxygen and nutrients to the tumor (Chi et al., 2009). 
Theoretically, the constriction of intratumor blood vessels reduces the intratumor blood 
flow and consequently the delivery of chemotherapeutics is reduced too, which 
counteracts the reduced supplies of nutrients and oxygen. An alternative hypothesis 
states that anti-angiogenic therapy may transiently normalize the highly abnormal tumor 
vasculature and improves the delivery and efficacy of concomitant cytotoxic therapy 
(Jain, 2005; Ma et al., 2011). According to this hypothesis, anti-angiogenic therapy may 
work by decreasing the permeability of tumor vasculature and decreasing the 
accumulation of interstitial fluid which result in a drop of the interstitial pressure and 
consequently leading to a uniform blood flow and diminished tumor hypoxia (Winkler 
et al., 2004). When anti-angiogenic therapy is accompanied with cytotoxic 
chemotherapy, the normalization of tumor vasculature may increase the tumor retention 
of the cytotoxic agent and hence increasing its efficacy (Ma et al., 2011). The 
normalization hypothesis is supported by the results of several research groups 
including (Winkler et al., 2004; Chabot et al., 2011; Hedlund et al., 2009). 
1.1.7 Recent Advances in Anti-angiogenesis Therapy: 
Since the inhibition of angiogenesis was launched, by Folkman in 1971, as a promising 
target for the treatment of different tumor types (Folkman, 1971), more than 40 anti-
angiogenic drugs have been tested in human cancer patients in clinical trials all over the 
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world. From functional point of view, these drugs can be classified into 3 groups 
(Figure 1.2): drugs that inhibit growth of endothelial cells such as endostatin and 
combretastatin A4, drugs that block angiogenesis signaling such as Avastin® and 
Interferon-alpha, and drugs that block ECM breakdown such as inhibitors of MMPs. 
The first class work by inducing apoptosis or inhibiting growth of endothelial cells, the 
second class inhibits the production of basic fibroblast growth factor (bFGF) and 
VEGF, whereas the last group works by inhibiting the breakdown of ECM and hence 
interferes with invasion and migration of endothelial cells. Other new drugs such as the 
tyrosine kinase inhibitors (Erlotinib, Sorafenib and Sunitinib) block the activity of 
multiple growth factor receptors such as VEGF and platelets derived growth factor 
receptors (PDGFR)  (Samant and Shevde, 2011).  
Seven anti-angiogenic agents have been approved as anti-cancer therapies by the 
American Food and Drug Administration (FDA). These agents fall in 2 categories 
including monoclonal antibodies directed against specific proangiogenic growth factors 
or their receptors, and small molecule tyrosine kinase inhibitors directed against 
proangiogenic growth factor receptors. Additionally, other molecules with unknown 
mechanism of action have been also reported such as mTOR inhibitors, proteasome 
inhibitors and thalidomide (Samant and Shevde, 2011). Another alternative approach in 
anti-angiogenic therapy is the metronomic chemotherapy i.e. the administration of low 
doses of conventional chemotherapy at regular intervals. Metronomic chemotherapy 
schedules work by inhibiting proliferation and survival of tumor endothelial cells, 
preventing the recruitment of endothelial progenitor cells (EPCs), and have anti-tumor 
activity (Chi et al., 2009; Samant and Shevde, 2011).  
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Figure 1.2 Targets of FDA approved angiogenesis inhibitors. Bevacizumab is anti-
VEGF antibody that binds to and limits the availability of VEGF. Cetuximab and 
Panitumumab block the activities of VEGF receptor. Trastuzumab is directed against 
tumor cells that deprives the effects of HER-2. Erlotinib, Sorafenib and Sunitinib are 
small molecule tyrosine kinase inhibitors that block the activity of multiple growth 
factor receptors such as VEGF and platelets derived growth factor receptors (PDGFR). 
Adapted from (Samant and Shevde, 2011). 
 
  
Although the monoclonal antibodies have been shown to effectively reduce 
tumor growth and metastasis, their therapeutic value is still questionable due to the 
required large doses (20 – 100 mg/kg). In addition, since these recombinant proteins 
have to be given frequently and on long term basis therefore it seems to be unpractical 
therapy (Cao, 2004b).  Hence, discovery of other alternatives such as small molecules 
from natural products, for example, seems to be more attractive and have the potential 
to replace the current anti-angiogenic agents. In this context, polyphenols including 
catechins, resveratrol, quercetin and many other compounds have been extensively 
studied and were found to effectively inhibit angiogenesis and tumor growth (Tan et al., 
2003; Zhou et al., 2005). Apart having lower side effects, these natural compounds are 
generally cheaper to produce. With respect to their pharmacokinetics, polyphenols are 
generally well absorbed after oral ingestion and have relatively long half-life and can be 
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considered as ideal therapeutics for long-term prevention and treatment of angiogenesis 
related diseases such as cancer (Cao, 2004a). 
1.1.8 Obstacles and Future Perspectives:   
Despite the success in some anti-angiogenic therapies, certain issues associated with 
this type of therapy need to be resolved including efficacy, toxicity, drug resistance and 
drug delivery to the tumors. Several studies have shown that anti-angiogenic therapy by 
itself is insufficient to cause shrinkage of pre-established tumors, and recent studies 
even showed that treatment with anti-angiogenic therapy alone such as Avastin can also 
enhance the invasiveness of glioblastoma tumor cells (Keunen et al., 2011). Another 
obstacle that is associated with both chemotherapy and anti-angiogenic therapy of 
cancer is the abnormal tumor vasculature; solid tumors have impaired blood flow due to 
the high interstitial pressure which interferes with the delivery of the therapeutic agents 
to tumor cells. Recently, a study employing animal models showed that anti-angiogenic 
agents such as Avastin transiently normalize the tumor vasculature and improves the 
intratumor blood flow and lead to increased retention of the cytotoxic therapeutics (Ma 
et al., 2011). Therefore, the occurrence of adverse effects when anti-angiogenic therapy 
is used alone and the improved retention of chemotherapeutics when used in 
combinations with anti-angiogenic therapy necessitate the combination of the 2 
therapeutic regimens in the treatment of cancer.  
Previously, it was believed that the clinical use of anti-angiogenic therapy may 
have fewer side effects than conventional chemotherapy for 2 reasons. First, under 
normal physiological conditions more than 99% of endothelial cells are quiescent. 
Second, physiological angiogenesis is distinct from arteriogenesis and 
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lymphangiogenesis. Therefore, it was proposed that anti-angiogenic therapy may 
interfere with physiologic angiogenesis associated with wound healing and menstrual 
cycle and will not cause severe side effects (Wu et al., 2008). However, the results of 
clinical trials and clinical use of anti-angiogenic therapy in cancer patients revealed the 
occurrence of severe toxicities including bleeding, delayed wound healing, thrombosis, 
hypertension, hypothyroidism and fatigue, proteinuria and edema, skin toxicity, 
leukopenia, lymphopenia, and immunomodulation (Wu et al., 2008). These side effects 
are caused by the nonselective activity of tyrosine kinase inhibitors and due to 
inhibition of VEGF pathways that play fundamental roles, either directly or indirectly, 
in maintaining normal functions of the kidneys, hematopoietic system, skin homeostasis 
and blood vessels (Wu et al., 2008).  
Novel strategies are needed to overcome the toxicities associated with anti-
angiogenic therapy. The enhanced permeability and retention effect and the acidic 
environment, encountered in most solid tumors, can be utilized to achieve selective 
delivery of cancer therapeutics to tumor cells. The leaky tumor vasculature due to 
presence of intercellular gaps with 100 – 600 nm (Hashizume et al., 2000), can be 
employed to passively deliver nanoparticles loaded with the therapeutic agents. Since 
the enhanced permeability and retention is unique to solid tumors, the nanoparticles 
delivery systems may be concentrated in the tumor microenvironment where the drug 
payload will be released. The selectivity of nanoparticles can be improved by active 
targeting, in which specific ligands to tumor cells such as folic acid can be linked on the 
surface of nanoparticles which targets them towards tumor cells with overexpression of 
folic acid receptors. Another targeting approach is by linking the drugs to their carries 
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via pH sensitive bonds that breakdown in the acidic microenvironment of tumors and 
therefore drug release will take place only in the acidic microenvironment of solid 
tumors (Cho et al., 2008). These approaches may help to effectively attack cancer and 
minimize the side effects due to the nonselective cytotoxicity.  
Of the biggest challenges that face anti-angiogenic therapy of cancer is the de 
novo or the acquired drug resistance. Previously it was believed that anti-angiogenic 
therapy has low likelihood of developing drug resistance since it targets the quiescent 
and the genetically stable endothelial cells. However, clinical use of anti-angiogenic 
therapeutics revealed that many tumors initially failed to respond to anti-angiogenic 
therapy and others develop resistance over time after a period of initial response (Azam 
et al., 2010). 
The mechanisms of resistance are not well understood but basically the presence 
of a complex network of angiogenesis signaling play fundamental roles in drug 
resistance. Since most anti-angiogenic therapies are directed towards inhibition of 
particular targets such as VEGF signaling, the angiogenic cascade can not be totally 
blocked and hence angiogenic signaling will continue through other alternative 
signaling pathways (Azam et al., 2010). Several mechanisms of resistance to anti-
angiogenic agents have been described including the presence of multiple positive 
modulators of angiogenesis such as VEGF, placental growth factor (PlGF), upregulation 
of the hypoxia pathway via stabilization of the HIF-1α, upregulation of proangiogenic 
stromal cells such as fibroblasts, pericytes and hematopoietic cells that augment tumor 
vasculature by secreting growth factors such as VEGF, bFGF and MMPs, pericytes 
regulate proliferation of endothelial cells and hence play a major role in retaining the 
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vascular integrity after termination of therapy, some anti-angiogenic compounds have 
hormetic effect i.e. they inhibit tumor growth at high concentration and stimulate tumor 
growth at lower concentrations, the loss of p53 tumor suppressor gene which plays 
important role in angiogenesis by modulating the expression of some key players in 
angiogenesis such as MMPs, overexpression of the membrane P-glycoproteins which 
work by efflux of the therapeutic agents and hence prevent their accumulation in the 
cytoplasm of target cells, and finally the tumor endothelial cells are genetically unstable 
and more resistant than normal endothelial cells (Azam et al., 2010).  
Several approaches have been tried to combat the lack of efficacy, toxicity and 
resistance in anti-angiogenic therapy such as combination of metronomic chemotherapy 
with anti-angiogenic therapy, the use of liposomes and nanoparticles to achieve 
selective delivery of the therapeutic agents to tumor cells. Additionally, combination of 
different anti-angiogenic agents with different mechanisms of action could be also tried, 
however it should be applied in the form of active drug delivery in order to diminish the 
nonspecific effects and hence to reduce the side effects.     
1.2 Colorectal Carcinoma: 
Colon cancer is a multi-step disease that occurs as a consequence of a series of 
pathologic changes that transform normal epithelial cells of the colon into invasive 
carcinoma (Figure 1.3). Several studies showed that this multi-step process is 
accompanied by specific mutations including the adenomatous polypsis coli (APC) 
gene, cyclooxygenase-2 (COX-2), (Kirsten-rat sarcoma virus) K-ras mutations, loss of 
the 18q21 gene, microsatellites instability and mutations in transforming growth factor-
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β II receptor (TGFβR2), and stabilization and translocation of β-catenin (Gustin and 
Brenner, 2002; Kobayashi et al., 2000; Kanwar et al., 2010).  
 
Figure 1.3 Stages of colon carcinogenesis. The figure shows the stages of colon cancer 
and the molecular changes that accompanied each stage, these changes can be 
considered as targets to prevent colon carcinogenesis. Adapted from (Pino and Chung, 
2010). 
 
 
The role of the APC suppressor gene in the early stages of colorectal carcinoma 
was extensively studied. Loss of function mutations of the APC gene is associated with 
accumulation of intracellular β-catenin which plays a role in cell adhesion and acts as a 
transcription factor of the Wnt signaling pathway (Henderson, 2000). Activation of 
Wnt/β-catenin signaling pathway leads to activation of T-cell factor/lymphoid 
enhancing factor-1 (TCF/LEF1) transcription factors and subsequently to expression of 
several target genes including c-Myc, cyclin D1 and COX-2 that have been implicated 
in tumorigenesis of colorectal carcinoma and several other cancers (Gehrke et al., 
2009).  
Cyclooxygenases (COXs) exist in 2 isoforms COX-1 and COX-2 and several 
studies have shown that COX-2 is overexpressed in human colon cancer and adenomas. 
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COX-2 converts arachidonic acid to prostaglandins which may stimulate proliferation 
of cancer cells, inhibit apoptosis and/or stimulate angiogenesis. Also the prostaglandins 
were found to work by inducing the production of some growth factors such as VEGF 
and hepatocyte growth factor that induce tumor angiogenesis and proliferation of the 
tumor cells (Ota et al., 2002).  
The role K-ras proto-oncogene in tumorigenesis of colon cancer has been 
extensively studied. K-ras proteins are located on the inner layer of plasma membrane 
and can be stimulated by extracellular signals such as growth factors and cytokines. In 
normal physiological conditions the activated K-ras proteins are inactivated after short 
period while their mutant counterparts are constitutively activated and continue to 
activate their downstream effector proteins.  Activity of K-ras is mediated via different 
signaling pathways including K-ras/RAF, K-ras/PI3-K and K-ras/RAL that are involved 
in regulation of proliferation, survival, invasion and metastasis, and angiogenesis 
(Castagnola and Giaretti, 2005). Oncogenic mutations in K-ras were found to play 
central roles in tumorigenesis of colorectal carcinoma and their presence indicates poor 
prognosis (Conlin et al., 2005).   
Other types of mutations are also involved in colon carcinogenesis including the 
chromosomal and microsatellites instability. The chromosomal instability results from a 
series of genetic alterations that involves activation of oncogenes such as K-ras and 
inactivation of tumor-suppressor genes, such as TP53, APC and deleted in colorectal 
carcinoma gene (DCC) located on chromosome 18q21, these mutations are associated 
with increased risk of relapse and death among colon cancer patients (Pino and Chung, 
2010). Whereas the microsatellites instabilities are caused by deficient DNA mismatch 
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repair and consequently lead to increased mutation frequency particularly in the 
repetitive microsatellite sequences (Gervaz et al., 2002; Castagnola and Giaretti, 2005).  
Frameshift mutations of TGFβR2 are encountered in more than 80% of colon cancer 
patients with microsatellite instability which make tumor cells more resistant to anti-
tumorigenic effects of TGF-β, thus inhibition of the TGF-β signaling pathway may 
contribute to the formation of primary colon tumors. In vitro experiments showed that 
inactivation of TGFβR2 in HCT 116 cells is associated with increased proliferation rate, 
and in vivo work indicated that mutant TGFβR2 may contribute to transformation of 
colorectal carcinoma (Grady et al., 2006).  
1.3 Major Signaling Pathways in Colon Carcinogenesis:  
1.3.1 Wnt/β-catenin Signaling Pathway:  
The Wingless-Int. (Wnt) signaling pathway plays a fundamental role in embryonic 
development, in regeneration of tissues and has a key role in cell-cell signaling (Logan 
and Nusse, 2004). Mutations in the Wnt pathway play a crucial role in cancer 
development and particularly in colon cancer. Almost 90% of all colon cancer cases are 
associated with mutations of APC tumor suppressor gene resulting in accumulation of 
Wnt/β-catenin (Giles et al., 2003). β-catenin complexes with TCF/LEF transcription 
factors and subsequently enhances the expression of downstream effector genes such as 
c-Myc, cyclin D1 and MMP genes which are involved in carcinogenesis and tumor 
angiogenesis (Gehrke et al., 2009). Therefore, downregulation of the Wnt pathway 
could be potential target in the treatment of various types of cancer including colon 
cancer.  
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1.3.2 Notch Signaling Pathway: 
Notch signaling pathway regulates the development of the central nervous system, the 
cardiovascular system, the endocrine system, bone development and tissue renewal. 
Notch signaling controls a range of cellular functions in normal physiological and 
pathological conditions including cell fate specification, differentiation, proliferation, 
apoptosis, adhesion, migration and angiogenesis (Bolos et al., 2007). Depending on 
signal strength, timing, cell type and the normal function of a given tissues, Notch can 
act as an oncogene or a tumor suppressor gene (Maillard and Pear, 2003). Recent 
studies in mutant APC mice showed that both of Wnt and Notch signaling pathways are 
activated which indicate that Notch may function downstream of the Wnt pathway in 
the intestine (Radtke and Clevers, 2005). Therefore, Notch signaling may provide an 
alternative therapeutic target and could be used in combination with Wnt inhibitors for 
treatment of colorectal carcinoma. 
1.3.3 P53 Signaling Pathway:  
The p53 tumor suppressor gene plays a fundamental role in cell cycle regulation and 
apoptosis. The activation of this pathway is associated with either cell cycle arrest or 
induction of apoptosis which depends on the strength and frequency of the signal 
(Haupt et al., 2003). Mutations in p53 suppressor gene are common in all cancers and 
loss of function mutations are encountered in more than 60% of cancer patients and 
associated with decreased sensitivity to chemotherapeutics (Machado-Silva et al., 2010) 
. p53 controls cell death by regulation of genes involved in both the extrinsic and 
intrinsic pathways of apoptosis either via transcriptional dependent or transcriptional-
independent mechanisms (Yu and Zhang, 2005). Therapeutic manipulation of p53 
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pathway is a promising strategy in cancer treatment and is expected to target a broad 
range of cancers with more selectivity and lower side effects. Several approaches 
including the use of small peptides or small molecules have been tried in order to 
reactivate the suppressed wild-type p53 or reverse the mutant into a wild-type 
p53(Machado-Silva et al., 2010).    
1.3.4 TGF-β Signaling Pathway:  
TGF-β signaling pathway has dual effects; tumor suppressor effects in the early stages 
of tumor development where it inhibits tumor progression by inducing apoptosis of 
tumor cells, and oncogenic effects in the late stages of tumorigenesis where it inhibits 
apoptosis, enhances metastasis and invasion of tumor cells, and provokes tumor 
angiogenesis (Sánchez-Capelo, 2005). In colorectal carcinoma, frameshift mutations in 
TGFβR2 are frequently encountered in more than 80% of cases with microsatellite 
instability. Inhibition of the TGF-β signaling pathway make tumor cells more resistant 
to anti-tumorigenic effects of TGF-β and may contribute to the formation of primary 
colon tumors (Grady et al., 2006). However, the opposing effects of TGF-β signaling 
pathway hold back the interest in this pathway as a therapeutic target of cancer.  
1.3.5 Cell Cycle (pRB/E2F) Signaling Pathway: 
Mutations that affect the retinoblastoma cell cycle signaling have been documented in 
nearly every type of adult cancer (Sellers and Kaelin, 1997). The retinoblastoma tumor 
suppressor gene encodes a protein called pRB which binds with a series of transcription 
factors termed E2F and forming dimmers that regulate the expression of several 
downstream effector genes involved in cell cycle control, DNA licensing and synthesis, 
mitosis, DNA repair and apoptosis (Stevaux and Dyson, 2002). The E2F transcription 
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factors were found to have both tumor suppressor and oncogenic effects which can be 
determined by the presence of active pRB suppressor gene. The concentration of E2F is 
increased in the presence of aberrant pRB and consequently increases cell proliferation 
and inhibits apoptosis via downregulation of p53. On the contrary, DNA damage which 
in the presence of wild-type gene can either induce cell cycle arrest or apoptosis, 
depending on the extent of DNA damage; pRB binds to the repressor E2Fs and induces 
G1 arrest and consequently DNA repair, or it binds to activator E2Fs where it induces 
apoptosis via activation of caspases 3 and 7, p53 and Apaf-1 and downregulation of the 
antiapoptotic proteins such as Bcl2 (Tsantoulis and Gorgoulis, 2005).  
1.3.6 NF-KB Signaling Pathway:  
The nuclear factor кB (NF-KB) represents a family of transcription factors that play a 
critical role in regulation of various biological processes such as immune and 
inflammatory responses, cell growth, migration, adhesion and apoptosis (Sun and Xiao, 
2003). NF-KB can be activated by several stimuli such as inflammatory cytokines, 
growth factors, DNA damaging agents, bacterial components and viral proteins (Pahl, 
1999). In normal physiological conditions NF-KB is only transiently activated and its 
deregulated activation has been encountered in a large variety of human malignancies 
such as leukemia, breast cancer, colon cancer, ovarian cancer, prostate cancer, liver 
cancer and melanoma (Sun and Xiao, 2003). Besides its role in oncogenesis, the NF-KB 
also plays crucial role in resistance of tumor cells to anti-cancer therapies (Scartozzi et 
al., 2007). The constitutive activity of NF-KB can be caused by genetic alterations in 
genes encoding NF-KB itself, or due to constitutive activation of the NF-KB-activating 
kinase. Increasing numbers of studies showed that inhibition of NF-KB can induce 
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apoptosis of tumor cells and hence NF-KB inhibitors are expected to enhance the anti-
tumor efficacy of chemotherapeutics (Sun and Xiao, 2003). 
1.3.7 Myc/Max Signaling Pathway: 
Myc is a transcription factor with dual effects; from one side it is required for the 
progression of cell cycle in normal cells and its overexpression in cancer cells acts as 
angiogenic switch. On the other hand, Myc/Max heterodimers induce intracellular 
transduction pathways required for induction of apoptosis (Nilsson and Cleveland, 
2003). Myc dimerizes with its partner protein Max and consequently binds to DNA 
where the complex modulates expression of the target genes including p53 and the 
mitochondrial proapoptotic proteins that work by enhancing release of cytochrome c 
and induction of apoptosis (Yang et al., 2009)  
1.3.8 Hypoxia Signaling Pathway: 
Hypoxia inducible factor is a master transcription factor that controls nutritional stress, 
angiogenesis, tumor metabolism, invasion, autophagy and cell death (Pouysségur et al., 
2006). Several studies showed that HIF-1α and HIF-2α are overexpressed in primary 
and metastatic human cancers and are associated with tumor angiogenesis and poor 
prognosis (Semenza, 2003). As solid tumors grow, the tumor mass in the center 
becomes far from oxygen and nutrients supply. Low concentration of oxygen activates 
HIF indirectly via specific cellular enzymes that sense the variations in oxygen tension 
(Po2) (Berra et al., 2006). Activation of HIF is a multi-step process that involves 
stabilization, nuclear translocation, heterodimerization, transcriptional activation and 
interaction with other proteins (Brahimi-Horn et al., 2005). In the nucleus, HIF binds to 
hypoxia-response elements where it regulates the expression of about 100 genes 
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including activation of genes involved in angiogenesis such as VEGF-A and Ang-2, 
activation of genes involved in cell invasion, migration and metastasis such as MMP-2, 
urokinase plasminogen activator receptor and E-cadherin, and inhibition of the m-TOR 
pathway (Pouysségur et al., 2006). These genes are associated with excessive tumor 
angiogenesis, metastasis and induction of autophagy and hence the tumors become 
more adaptive with nutrient and oxygen deprivation and more resistant to chemotherapy 
(Melillo, 2007; Semenza, 2003). The critical role of HIF in development of primary and 
metastatic tumor growth makes it as a good target in cancer therapy. However, its 
fundamental role in inflammation may hamper this strategy as the prolonged use of 
HIF-1 inhibitors is associated with severe immunodeficiency. Thus, it seems more 
attractive to target the HIF gene products rather than targeting HIF itself (Pouysségur et 
al., 2006).  
1.3.9 MAPK Signaling Pathways: 
The mitogen-activated protein kinases (MAPKs) control many and fundamental 
physiological functions. MAPKs are sub-divided into 4 sub-groups including the 
extracellular regulated kinase 1 and 2 (ERK 1 and 2), ERK5, p38 MAPKs and the c-Jun 
amino terminal kinase (MAPK/JNK) (Shen et al., 2001; Johnson and Lapadat, 2002). 
MAPKs signaling play fundamental roles in cell proliferation, differentiation, survival 
and cell death (Chang and Karin, 2001; Qiao et al., 2001). The role of MARK/ERK 
pathway has been extensively studied and devastating lines of evidence indicate an 
oncogenic, mitogenic, and prosurvival roles and hence it is believed that MAPKs have a 
central role in development of some types of cancer such as colon and malignant 
melanoma (Davies et al., 2002). So far inhibitors of MAPK/ERK pathway are 
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considered as potential therapeutics of several types of cancer. On the other hand, some 
evidence suggests that the activation of MAPK/ERK pathway rather than its inhibition 
induced cell cycle arrest and/or apoptosis and therefore may provide a therapeutic target 
of different types of cancer such as small cell lung carcinoma (Ravi et al., 1998), 
osteosarcoma (Yang et al., 2008) and pancreatic cancer (Sahu et al., 2009). 
Furthermore, activation of the MAPK/ERK pathway is implicated in inducing apoptotic 
effects as a consequence of DNA damage caused by cisplatin (Wang et al., 2000), 
etoposide (Stefanelli et al., 2002), doxorubicin, and ionizing and ultraviolet irradiation 
(Tang et al., 2002).  
The mechanism of the MAPK/ERK mediated apoptosis was recently reviewed 
by Cagnol and Chambard (Cagnol and Chambard, 2010); both the intrinsic and extrinsic 
pathways of apoptosis can be induced by the activated ERK that depends on the nature 
of the treatment and cell type. Moreover, ERK pathway was found to induce 
cytochrome c release by modulation of the Bcl2 protein family and more specifically by 
downregulation of the antiapoptotic proteins and upregulation of the proapoptotic 
proteins. In addition to the direct effect on the apoptotic mediators, activation of ERK 
pathway is associated with increased stability and activity of p53, and increased 
stability of c-Myc which in turn increases the proapoptotic effects of p53.  
 1.4 Colon Cancer Chemotherapeutics Strategies: 
To date, no curative therapy is available for colon cancer and most types of cancer as 
well and the available treatments are meant to prolong the disease-free interval. 
Treatment of colorectal carcinoma is based on the use of cytotoxic agents including 5-
fluorouracil (5-FU), oxaliplatin (OX), irinotecan, leucovorin (LV) and capecitabine 
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(Cap). Different combinations of these agents were extensively studied in phase II and 
phase III clinical trials such as IFL (irinotecan, 5-FU and LV), FOLFOX (5-FU, OX 
and LV), FOLFIRI (5-FU, LV and irinotecan) and CapOx (capecitabine/oxaliplatin). 
All of these combinations showed better therapeutic outcome than the monotherapy 
(Cercek and Saltz, 2008). After the development of the monoclonal antibodies 
bevacizumab (anti-VEGF), panitumumab (human anti-EGFR) and Cetuximab (chimeric 
human-mouse anti-EGFR), several combinations of these agents with the cytotoxic 
drugs have been studied in phase II and phase III clinical trials. In general, the results 
showed that combination of either anti-VEGF or anti-EGFR antibodies with the 
cytotoxic agents resulted in better therapeutic outcome than each individual therapy. 
However, the combination of anti-VEGF and anti-EGFR with irinotecan was found to 
have a negative impact on the therapeutic outcome which may depend on the molecular 
status of the tumor such as the presence of wild-type or mutant K-ras (Cercek and Saltz, 
2008).  
1.5 Polymeric Nanoparticles as Drug Delivery Systems: 
Polymeric nanoparticles (PNPs) represent one of the promising controlled-release drug 
delivery systems that can be utilized in the treatment of different human diseases. The 
controlled-release drug delivery systems are aimed to enhance bioavailability, improve 
efficacy, reduce toxicity, and improve patient compliance and convenience, and hence 
are more advantageous than the conventional dosage forms.  
1.5.1 Definition of Nanoparticles: 
NPs including the nanospheres and nanocapsules are often defined as solid colloidal 
particles in the range of 10 – 1000 nm. Where the nanospheres are solid matrices whose 
